Australia markets closed
  • ALL ORDS

    7,239.40
    +30.40 (+0.42%)
     
  • ASX 200

    7,014.20
    +31.50 (+0.45%)
     
  • AUD/USD

    0.7738
    +0.0007 (+0.09%)
     
  • OIL

    64.48
    +0.66 (+1.03%)
     
  • GOLD

    1,833.80
    +9.80 (+0.54%)
     
  • BTC-AUD

    65,196.61
    +1,052.57 (+1.64%)
     
  • CMC Crypto 200

    1,397.13
    +9.22 (+0.66%)
     
  • AUD/EUR

    0.6387
    -0.0007 (-0.11%)
     
  • AUD/NZD

    1.0742
    -0.0010 (-0.09%)
     
  • NZX 50

    12,367.86
    -60.26 (-0.48%)
     
  • NASDAQ

    13,109.15
    +107.51 (+0.83%)
     
  • FTSE

    7,008.35
    +45.02 (+0.65%)
     
  • Dow Jones

    34,021.45
    +433.79 (+1.29%)
     
  • DAX

    15,296.29
    +96.61 (+0.64%)
     
  • Hang Seng

    28,027.57
    +308.90 (+1.11%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     

Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
  • Oops!
    Something went wrong.
    Please try again later.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, April 17, 2021 at 7 p.m. Eastern Time across the United States. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. Eastern Time in 73 million homes.

To view the interview segment, please visit: https://youtu.be/9M0B8RPahYs

"The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Virios Therapeutics

Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as fibromyalgia ("FM"). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 ("HSV-1") have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease ("IBS"), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate ("IMC-1") is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.

Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2 clinical trial. These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2B trial ("FORTRESS") designed to set the stage for registrational studies. The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies. For more information, please visit www.virios.com.

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210416005036/en/

Contacts

Investor Relations Contact:
Dave Gentry
RedChip Companies Inc.
407-491-4498
dave@redchip.com

Company Contact:
Jenny Kobin
IR@Virios.com